Published in Chest Surg Clin N Am on February 01, 1998
A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer (2011) 1.66
Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques. Arch Surg (2012) 1.41
Surgery and sentinel lymph node biopsy. Semin Oncol (2007) 0.85
Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. Ann Surg Oncol (2009) 0.84
Grating-based phase-contrast imaging of tumor angiogenesis in lung metastases. PLoS One (2015) 0.82
Radiofrequency ablation of pulmonary tumours: current status. Cancer Imaging (2008) 0.78
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg (1994) 8.85
Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg (1995) 4.37
Impaired immunologic reactivity and recurrence following cancer surgery. Cancer (1970) 3.77
Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg (1995) 3.62
Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery (1968) 3.56
IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. J Immunol (1989) 2.86
Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry (1993) 2.38
Occult tumor cells in the lymph nodes of patients with pathological stage I malignant melanoma. An immunohistological study. Am J Surg Pathol (1988) 2.32
BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg (1974) 2.14
Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol (1999) 2.08
Parathyroid carcinoma: a collective review. Ann Surg (1969) 1.94
Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg (1996) 1.91
The nature of immune complexes in human cancer sera. J Immunol (1977) 1.88
A rational approach to the surgical management of melanoma. Ann Surg (1977) 1.88
Complications of BCG immunotherapy in patients with cancer. N Engl J Med (1973) 1.72
Tumor doubling time: a selection factor for pulmonary resection of metastatic melanoma. J Surg Oncol (1998) 1.71
Radiofrequency ablation: a minimally invasive technique with multiple applications. Cancer J Sci Am (1999) 1.70
Immunological factors in human sarcomas and melanomas: a rational basis for immunotherapy. Ann Surg (1970) 1.68
Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol (1995) 1.66
Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences? Ann Surg Oncol (2000) 1.64
Long-term survival after complete resection of melanoma metastatic to the adrenal gland. Ann Surg Oncol (1999) 1.63
Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line. J Exp Med (1989) 1.62
Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol (2000) 1.59
Human osteosarcomas: immunologic evidence suggesting an associated infectious agent. Science (1968) 1.58
Detection of antibody and complement complexed in vivo on membranes of human cancer cells by mixed hemadsorption techniques. Cancer Res (1975) 1.58
Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma. N Engl J Med (1976) 1.57
Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol (2001) 1.57
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Sentinel lymph nodes show profound downregulation of antigen-presenting cells of the paracortex: implications for tumor biology and treatment. Mod Pathol (2001) 1.48
Parotid region lymphatic mapping and sentinel lymphadenectomy for cutaneous melanoma. Ann Surg Oncol (1999) 1.47
Is amputation necessary for sarcomas? A seven-year experience with limb salvage. Ann Surg (1980) 1.46
Is adjuvant radiotherapy necessary after positive lymph node dissection in head and neck melanomas? Ann Surg Oncol (2000) 1.43
Current management of malignant melanoma. Ann Surg (1990) 1.43
Hepatic resection of metastatic colorectal carcinoma: a ten-year experience. Arch Surg (1982) 1.43
Serum TA90 antigen-antibody complex as a surrogate marker for the efficacy of a polyvalent allogeneic whole-cell vaccine (CancerVax) in melanoma. Ann Surg Oncol (2001) 1.42
Human liposarcomas: tissue cultures containing foci of transformed cells with viral particles. Science (1969) 1.42
Anti-tyrosinase-related protein-2 immune response in vitiligo patients and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol (1998) 1.41
Role of percutaneous fine-needle aspiration biopsy in suspected intrathoracic malignancy. Ann Thorac Surg (1991) 1.40
Retroperitoneal sarcomas: a reappraisal of treatment. J Surg Oncol (1981) 1.40
Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res (2000) 1.38
Granulomatous hepatitis: a complication of B.C.G. immunotherapy. Lancet (1973) 1.38
Enhancement of complement-dependent cytotoxicity by polyvalent melanoma cell vaccine (CancerVax): correlation with survival. Ann Surg Oncol (1999) 1.38
Will the true sentinel node please stand? Ann Surg Oncol (1999) 1.35
Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res (1997) 1.35
Neurofibrosarcoma. Cancer (1980) 1.33
Universal application of intraoperative lymphatic mapping and sentinel lymphadenectomy in solid neoplasms. Cancer J Sci Am (1999) 1.30
Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst (1981) 1.30
Advances in the treatment of sarcomas of the extremity. Current status of limb salvage. Cancer (1984) 1.28
Immunologic studies of human sarcomas: Additional evidence suggesting an associated sarcoma virus. Cancer (1970) 1.27
Correlation of in vivo and in vitro assays of immunocompetence in cancer patients. Cancer Res (1974) 1.27
Clinical aspects of unknown primary melanoma. Ann Surg (1980) 1.27
Lymphatic drainage of skin to a sentinel lymph node in a feline model. Ann Surg (1991) 1.27
Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol (1999) 1.27
Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. J Clin Oncol (2001) 1.26
Natural antibody in human serum to a neoantigen in human cultured cells grown in fetal bovine serum. J Natl Cancer Inst (1974) 1.23
Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol (1999) 1.22
Pulmonary resection for metastatic sarcoma. Am J Surg (1980) 1.22
Melanoma from unknown primary site and amelanotic melanoma. Semin Oncol (1982) 1.20
Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. Cancer (2001) 1.19
A membrane antigen common to human cancer and fetal brain tissues. Cancer Res (1976) 1.19
Metastasectomy for recurrent stage IV melanoma. J Surg Oncol (1999) 1.18
Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: a proposed algorithm. Arch Surg (2000) 1.18
Immunologic abnormalities in head and neck cancer. Am J Surg (1974) 1.17
Gangliosides of human melanoma. J Natl Cancer Inst (1987) 1.17
Cell-mediated immunity is depressed following cardiopulmonary bypass. Ann Thorac Surg (1981) 1.16
Factors prognostic for survival in patients with malignant melanoma spread to the regional lymph nodes. Ann Surg (1982) 1.15
The Augsburg Consensus. Techniques of lymphatic mapping, sentinel lymphadenectomy, and completion lymphadenectomy in cutaneous malignancies. Cancer (2000) 1.15
Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science (1974) 1.15
Lack of correlation between skin reactivity to dinitrochlorobenzene and croton oil in patients with cancer. N Engl J Med (1975) 1.14
Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg (2001) 1.14
Prognostic significance of tumor doubling time in evaluating operability in pulmonary metastatic disease. J Thorac Cardiovasc Surg (1971) 1.14
Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res (1999) 1.14
Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene (2009) 1.14
Immunologic and virus studies with human sarcomas. Surgery (1969) 1.13
Natural history of surgically treated mucosal melanoma. Am J Surg (1987) 1.13
Nodal nevi and cutaneous melanomas. Am J Surg Pathol (1996) 1.13
Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg (1995) 1.13
Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res (1998) 1.12
Limb salvage for skeletal and soft tissue sarcomas. Multidisciplinary preoperative therapy. Cancer (1984) 1.12
Regional lymphatic drainage in primary malignant melanoma of the trunk determined by colloidal gold scanning. Surg Forum (1977) 1.11
Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol (1997) 1.11
Gamma knife radiosurgery for metastatic melanoma: an analysis of survival, outcome, and complications. Neurosurgery (1999) 1.10
Immunogenicity of melanoma-associated gangliosides in cancer patients. Int J Cancer (1985) 1.10
Validation of lymphatic mapping in colorectal cancer: in vivo, ex vivo, and laparoscopic techniques. Ann Surg Oncol (2001) 1.10
Sequential evaluation of general immune competence in cancer patients: correlation with clinical course. Cancer (1975) 1.09
Normal tissue and solid tumor effects of hyperthermia in animal models and clinical trials. Cancer Res (1979) 1.09
Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay. Cancer Res (1984) 1.09
Immunological studies with human neoplasms. J Reticuloendothel Soc (1971) 1.08
Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture. Cancer Res (1982) 1.08
Regional lymph node metastases and the level of invasion of primary melanoma. Cancer (1976) 1.08
Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms. Arch Surg (2000) 1.07
Thermochemotherapy for melanoma metastases in liver. Cancer (1982) 1.07
The determination of lymph shed by colloidal gold scanning in patients with malignant melanoma: a preliminary study. Surgery (1978) 1.05
Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res (1990) 1.05
Management of patients with radiation-induced pericarditis with effusion: a note on the development of aortic regurgitation in two of them. Chest (1973) 1.05
Lymphatic mapping and sentinel lymphadenectomy for melanoma. Semin Surg Oncol (1998) 1.05
Delayed intestinal obstruction following treatment for cancer. Cancer (1970) 1.05
Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur J Cancer (2002) 1.05
Immunotherapy of malignancy in humans. Current status. JAMA (1975) 1.05